Therapy with anti-CTLA-4 monoclonal antibodies has been investigated in both phase I/II trials, as well as two notable phase III trials in the setting of advanced prostate cancer—one in chemotherapy-naïve patients and the other in patients that had disease progression while on docetaxel [68, 69]. This evidence concerns the gene CTLA4 and Familial prostate cancer.